CEL-SCI Corporation (CVM)Healthcare | Biotechnology | Vienna, United States | NYSE American
4.95 USD
+0.31
(6.681%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.45 -0.50 (-0.500%) ⇩ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:56 p.m. EDT
CEL-SCI Corporation (CVM) shows a volatile short-term price trend with recent dips and spikes, indicating potential momentum opportunities. However, the overall risk is high, and the forward PE and EPS are negative, suggesting financial instability. The stock has been affected by news about public offerings and insider buying, which could indicate mixed signals for short-term traders. For long-term investors, the fundamentals are weak with negative returns on assets and equity, making it a risky proposition. There are no dividends to consider, which further reduces its appeal for income-focused investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.143426 |
| MSTL | 0.225112 |
| AutoETS | 0.234946 |
| AutoARIMA | 0.236365 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 3.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.338 |
| Excess Kurtosis | -0.90 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 1996-08-27 |
| Debt to Equity Ratio | 81.748 |
| Market Cap | 41,866,936 |
| Forward P/E | -5.38 |
| Beta | 1.00 |
| Website | https://cel-sci.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40512818 |
| Address1 | 8,229 Boone Boulevard |
| Address2 | Suite 802 |
| All Time High | 646,875.0 |
| All Time Low | 1.98 |
| Ask | 4.95 |
| Ask Size | 100 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 51,710 |
| Average Daily Volume3 Month | 53,500 |
| Average Volume | 53,500 |
| Average Volume10Days | 51,710 |
| Beta | 0.998 |
| Bid | 4.32 |
| Bid Size | 200 |
| Board Risk | 9 |
| Book Value | 1.383 |
| City | Vienna |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.95 |
| Current Ratio | 1.395 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.95 |
| Day Low | 4.667 |
| Debt To Equity | 81.748 |
| Display Name | CEL-SCI |
| Dividend Date | 1,497,484,800 |
| Earnings Timestamp End | 1,770,903,000 |
| Earnings Timestamp Start | 1,770,903,000 |
| Ebitda | -21,230,740 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.02 |
| Enterprise Value | 42,881,136 |
| Eps Current Year | -4.16 |
| Eps Forward | -0.92 |
| Eps Trailing Twelve Months | -3.7 |
| Esg Populated | 0 |
| Ex Dividend Date | 841,190,400 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.1116 |
| Fifty Day Average Change | 0.8383999 |
| Fifty Day Average Change Percent | 0.20391086 |
| Fifty Two Week Change Percent | -40.512817 |
| Fifty Two Week High | 13.48 |
| Fifty Two Week High Change | -8.53 |
| Fifty Two Week High Change Percent | -0.6327893 |
| Fifty Two Week Low | 1.98 |
| Fifty Two Week Low Change | 2.9699998 |
| Fifty Two Week Low Change Percent | 1.4999999 |
| Fifty Two Week Range | 1.98 - 13.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 439,741,800,000 |
| Float Shares | 7,944,056 |
| Forward Eps | -0.92 |
| Forward P E | -5.3804345 |
| Free Cashflow | -8,943,390 |
| Full Exchange Name | NYSE American |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -15,134,144 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08168 |
| Held Percent Institutions | 0.09137 |
| Implied Shares Outstanding | 8,457,967 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,747,699,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. |
| Long Name | CEL-SCI Corporation |
| Market | us_market |
| Market Cap | 41,866,936 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_258746 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -23,807,440 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 39,244,966 |
| Number Of Analyst Opinions | 1 |
| Open | 4.69 |
| Operating Cashflow | -17,001,868 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.12 |
| Phone | 703 506 9460 |
| Post Market Change | -0.5 |
| Post Market Change Percent | -10.10101 |
| Post Market Price | 4.45 |
| Post Market Time | 1,776,470,392 |
| Previous Close | 4.64 |
| Price Eps Current Year | -1.1899039 |
| Price Hint | 4 |
| Price To Book | 3.5791755 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.247 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.31 |
| Regular Market Change Percent | 6.68103 |
| Regular Market Day High | 4.95 |
| Regular Market Day Low | 4.667 |
| Regular Market Day Range | 4.667 - 4.95 |
| Regular Market Open | 4.69 |
| Regular Market Previous Close | 4.64 |
| Regular Market Price | 4.95 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 41,457 |
| Return On Assets | -0.59898 |
| Return On Equity | -2.12119 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 8,457,967 |
| Shares Percent Shares Out | 0.0554 |
| Shares Short | 468,191 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 501,929 |
| Short Name | Cel-Sci Corporation |
| Short Percent Of Float | 0.0558 |
| Short Ratio | 12.8 |
| Source Interval | 15 |
| State | VA |
| Symbol | CVM |
| Target High Price | 25.0 |
| Target Low Price | 25.0 |
| Target Mean Price | 25.0 |
| Target Median Price | 25.0 |
| Total Cash | 6,284,667 |
| Total Cash Per Share | 0.777 |
| Total Debt | 9,105,615 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.50455 |
| Two Hundred Day Average Change | -1.5545502 |
| Two Hundred Day Average Change Percent | -0.23899427 |
| Type Disp | Equity |
| Volume | 41,457 |
| Website | https://cel-sci.com |
| Zip | 22,182 |